ASCO GU 2023
Bladder preservation strategies - promising data but no change in SoC yet?!
HCRN GU 16-257, RETAIN
ASCO GU 2023
Bladder preservation strategies - promising data but no…
IMvigor130, JAVELIN-Bladder100, TROPHY-U1-cohort3
ASCO GU 2023
New updates on immunocheckpoint inhibitors and ADCs -…
CheckMate-257
ASCO GU 2023
Robust DFS benefit, but lack of OS data leaves open…
IMvigor130
ASCO GU 2023
PD-1 as combo in 1st line
IMvigor130
ASCO GU 2023
Atezo monotherapy for mUC
KEYNOTE-057
ASCO GU 2023
Pembro for HR NMIBC
IMvigor-130
ASCO GU 2023
No final OS difference - but subgroups may benefit from…
Javelin Bladder 100; Trophy-U-01 Cohort 3
ASCO GU 2023
Urothelial cancer highlights from ASCO GU23
HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100
ASCO GU 2023
Re-shaping bladder cancer treatment
IMvigor130
ASCO GU 2023
IMvigor130: final OS
IMvigor130
ASCO GU 2023
Final overall survival
HCRN GU14-188
ASCO GU 2023
Benefit of neoadjuvant pembro for CE and CI patients
IMvigor130, CheckMate 274, UNITE
ASCO GU 2023
No change in SoC, but new genomic predictors for EV…
JAVELIN Bladder
ASCO GU 2023
Update / German Real World Data M1 BC
IMvigor 130
ASCO GU 2023
Final OS data show no significant benefit for chemo…
Keynote-057
ASCO GU 2023
New data for pembro in HR NIMBC
Keynote-057
ASCO GU 2023
Pembrolizumab in HR NIMBC
Keynote-057; CheckMate 274
ASCO GU 2023
NMIBC highlights from ASCO GU23
THOR-2
ASCO GU 2023
Urothelial cancer - hidden gems of the poster session
CheckMate 274
ASCO GU 2023
3 yrs outcome of Nivo for adjuvant therapy
CheckMate 274
ASCO GU 2023
Checkpoint inhibition in adjuvant therapy
CheckMate-257
ASCO GU 2023
Impressive DFS with adjuvant Nivo in biomarker-positive…
IMvigor130, CheckMate 274
ASCO GU 2023
The bladder cancer highlights of ASCO GU
CheckMate 274
ASCO GU 2023
Exciting survival data for adjuvant NIVO
IMvigor130, CheckMate 274
ASCO GU 2023
The bladder cancer highlights of ASCO GU
Keynote-057
ASCO GU 2023
BCG yanıtsız yüksek riskli KİOMK tedavisinde…
ASCO GU 2023
Los aspectos más destacados del ASCO GU 2023 en cáncer…
TRITON3
ASCO GU 2023
PARPi are effective in PCa - which subgroups benefits…
Keynote-057, CheckMate 274, Javelin Bladder 100, Trophy-U-01 Cohort 3
ASCO GU 2023
Επισημάνσεις για τον καρκίνο του ουροθηλίου από την…
HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100
ASCO GU 2023
Refinando el tratamiento del cancere vejiga
ARASENS
ASCO GU 2023
Triplet combination - all-comer therapy or high risk…
TRITON3, MAGNITUDE
ASCO GU 2023
Benefits and risks of precision medicine with PARPi
TALAPRO-2, PROpel
ASCO GU 2023
BRCA mutations in mCRPC - the importance of biomarkers…
ARASENS
ASCO GU 2023
Benefit in all groups
NRG/RTOG
ASCO GU 2023
MMAI - a superior prognostic marker for high risk…
ARASENS
ASCO GU 2023
ARASENS: triple independent of volume and risk
ASCO GU 2023
New ways to target androgen receptor signaling
FORMULA-509
ASCO GU 2023
Intensification of salvage therapy in high risk…
Arasens
ASCO GU 2023
Monotherapy is not any longer standard of care
ASCO GU 2023
Normal baseline testosterone level is a strong…
ARASENS
ASCO GU 2023
ARASENS - post-hoc subgroup analysis
ARASENS
ASCO GU 2023
Doublet or all-in: the solution for all patients?
ASCO GU 2023
Surgery vs. Radiation for N1 PCa: who wins?
FORMULA-509
ASCO GU 2023
PARP and testing
Formula 509
ASCO GU 2023
Formula 509: Racing to a better straegy for…
ASCO GU 2023
Controversy in ADT roundtable
ARASENS; PEACE-1
ASCO GU 2023
mHSPC - new standard and more insights
TRITON3
ASCO GU 2023
Rucaparib - ready for clinical practice in BRCAmut…
Talapro-2
ASCO GU 2023
Tiebreaker for previous trials
TALAPRO-2
ASCO GU 2023
PARPi combo: all-comer treatment for mCRPC
MAGNITUDE
ASCO GU 2023
PARPi & ARPi with wonderful data
TRITON3
ASCO GU 2023
Rucaparib: treatment option for biomarker-selected…
TRITON3, Talapro2, PROpel
ASCO GU 2023
PARPi combination in mCRPC
TRITON3
ASCO GU 2023
Rucaparib - the new player?
TALAPRO-2
ASCO GU 2023
TALA in 1st line for all patients with mCRPC
Talapro-2
ASCO GU 2023
TALA ENZO with improved PFS in mCRPC
Talapro-2
ASCO GU 2023
Encouraging results for Talazoparib
TRITON3
ASCO GU 2023
PARPi are effective in PCa - which subgroup benefits…
TALAPRO-2; PROpel
ASCO GU 2023
PARPi combo approval for all-comers - balancing…
TRITON3
ASCO GU 2023
PARPi study with different design
PROpel
ASCO GU 2023
Propel - final OS
TRITON3
ASCO GU 2023
Ny PARP hämmar studie med anna design
MAGNITUDE
ASCO GU 2023
PARPi & ARPi με υπέροχα δεδομένα
PACE-A
ASCO GU 2023
Lokalize prostat kanserinde cerrahi ile SBRT…
Formula 509
ASCO GU 2023
RP sonrası kurtarma RT ile GnRH Analog ABİ APA…
ASCO GU 2023
edavi öncesi normal testosteron seviyesi ADT sonrası…
Talapro-2
ASCO GU 2023
TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha…
ASCO GU 2023
miR371'in orşiektomi sonrası tedavi seçimini…
NRG/RTOG
ASCO GU 2023
MMAI- Yüksek riskli prostat kanserinde üstün bir…
ASCO GU 2023
ASCO GU 2023
Nya vägar att blockera androgenreceptor signalering
COSMIC-313, CaboPoint
ASCO GU 2023
Novel updates on cabozantinib in advance RCC
ZIRCON
ASCO GU 2023
Theranostics in RCC - usefull tools for ccRCC?!
CheckMate_9ER
ASCO GU 2023
Updated data of CheckMate 9ER - impact on real-world…
CheckMate_9ER
ASCO GU 2023
Reassuring update of CM9ER with longer follow up
CheckMate 9ER, CaboPoint
ASCO GU 2023
Longer FU confirms significant benefit of Nivo-Cabo,…
COSMIC-313; CheckMate_9ER
ASCO GU 2023
New therapy choices for renal cell cancer patients
IMDC
ASCO GU 2023
Outcomes of patients with brain metastases treated with…
ZIRCON
ASCO GU 2023
Zircon-PET in RCC
COSMIC-313
ASCO GU 2023
Hypothesis-generating differences in risks groups
CaboPoint
ASCO GU 2023
First prospective data on 2nd line therapy after IO…
ASCO GU 2023
Refining prediction of stage I seminoma
ASCO GU 2023
High accuracy of miR371 to guide treatment selection…
ASCO 2023
microbiom & CPI perspectives
ASCO GU 2023
Mejorando la estimacion pronostica en Seminoma Estadio…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!